Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who

  • 0 views
  • 07 Oct, 2022
  • 56 locations
Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) (LAMPARA)

The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To

chromogranin a
pheochromocytoma
catecholamines
adrenal pheochromocytoma
metastatic disease
  • 0 views
  • 21 Oct, 2022
  • 2 locations
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA

liver metastasis
neutrophil count
selective internal radiation therapy
somatostatin
cabozantinib
  • 0 views
  • 12 Sep, 2021
  • 1 location
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.

lanreotide
fasting
igf1
  • 0 views
  • 11 Apr, 2023
  • 6 locations
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with

  • 0 views
  • 04 Oct, 2022
  • 1 location